Fenofibrate causes elevation of betaine excretion but not excretion of other osmolytes by healthy adults

Journal of Clinical Lipidology

Volumn 8, Issue 4, 2014, Pages 433-440

  Lever, Michael ^a,b   McEntyre, Christopher J ^a   George, Peter M ^a,b   Slow, Sandy ^a,b   Chambers, Stephen T ^a,b   Foucher, Christelle ^c  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Clinsciences   (France)

Author keywords

Betaine; Carnitine; Fenofibrate; Fibrate; Myo inositol; One carbon metabolism; Osmolyte; Trimethylamine n oxide

Indexed keywords

ACETYLCARNITINE; BETAINE; CARNITINE; CHOLINE; CREATININE; DIMETHYLGLYCINE; FENOFIBRATE; INOSITOL; OSMOLITE; TAURINE; TRIMETHYLAMINE OXIDE; ANTILIPEMIC AGENT; SARCOSINE;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; ANALOGS AND DERIVATIVES; DYSLIPIDEMIAS; MASS SPECTROMETRY; MIDDLE AGED; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BETAINE; CHOLINE; CHROMATOGRAPHY, LIQUID; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MASS SPECTROMETRY; MIDDLE AGED; SARCOSINE;

EID: 84905976231     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.04.001     Document Type: Article

References (31)

1. Lever M, George PM, Slow S, et al. Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther. 2009;23:395-440.
2. Lever M, George PM, Atkinson W, et al. The contrasting relationships between betaine and homocysteine in two clinical cohorts are associated with plasma lipids and drug treatments. PLoS ONE. 2012;7:e32460.
3. Lever M, George PM, Elmslie JL, et al. Betaine and secondary events in an acute coronary syndrome cohort. PLoS ONE. 2012;7:e37883.
4. Lever M, Slow S. The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem. 2010; 43:732-744.
5. Lever M, George PM, Slow S, et al. Fibrates plus betaine: a winning combination? NZ Med J. 2010;123:74-78.
6. European Food Safety Authority. Scientific opinion on the substantiation of health claims related to betaine and contribution to normal homocysteine metabolism (ID 4325) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2052.
7. Ian Hamilton-Craig I, Kostner KM, Woodhouse S, Colquhoun D. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations. Int J Evid Based Healthcare. 2012;10:181-190.
8. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969-2989.
9. Hottelart C, El Esper N, Archard JM, Pruna A, Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie. 1999;20:41-44.
10. Foucher C, Schiffer E, Mischak H, Ansquer J-C, Wilbraham D. Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers. Proteomics Clin Appl. 2011;5:159-166.
11. Bablok W, Passing H, Bender R, Schneider B. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem. 1988;26:783-790.
12. Broeders N, Knoop C, Antoine M, Tielemans, Abramowicz D. Fibrateinduced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000;15:1993-1999.
13. Lever M, Sizeland PC, Bason LM, Hayman CM, Robson RA, Chambers ST. Abnormal glycine betaine content of the blood and urine of diabetic and renal patients. Clin Chim Acta. 1994;230:69-79.
14. Lever M, George PM, Dellow WJ, Scott RS, Chambers ST. Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. Metabolism. 2005;54:1-14.
15. Schartum-Hansen H, Ueland PM, Pedersen ER, et al. Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients. PLoS ONE. 2013;8:e469454.
16. Lever M, George PM, Atkinson W, et al. Plasma lipids and betaine are related in an Acute Coronary Syndrome Cohort. PLoS ONE. 2011;6: e21666.
17. Konstantinova SV, Tell GS, Vollset SE, Nygárd O, Bleie Ø, Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr. 2008;138:914-920.
18. Lever M, Slow S, George PM, Chambers ST. Betaine excretion correlates with plasma homocysteine when plasma lipids are elevated. Clin Biochem. 2012;45:154-156.
19. Barter PJ, Rye K-A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008;28:39-46.
20. Flory JH, Ellenberg S, Szapary PO, Strom BL, Hennessy S. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care. 2009;32:547-551.
21. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472: 57-63.
22. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Med. 2013;19:576-585.
23. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013; 368:1575-1584.
24. Bell JD, Lee JA, Lee HA, Sadler PJ, Wilkie, Woodham RH. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim Biophys Acta. 1991;1096:101-107.
25. Bain MA, Faull R, Fornasini G, Milne RW, Evans AM. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant. 2006;21:1300-1304.
26. Lever M, Storer MK, Lewis JG, George PM, Chambers ST. Plasma betaine concentrations correlate with plasma cortisol but not with C-reactive protein in an elderly population. Clin Chem Lab Med. 2012;50:1635-1640.
27. Pekkinen J, Olli K, Huotari A, et al. Betaine supplementation causes increase in carnitine metabolites in the muscle and liver of mice fed a high-fat diet as studied by nontargeted LC-MS metabolomics approach. Molec Nutr Food Res. 2013;57:1959-1968.
28. Dellow WJ, Chambers ST, Lever M, Lunt H, Robson RA. Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia. Diab Res Clin Pract. 1999;43:91-99.
29. Yoshii H, Uchino H, Ohmura C, Watanabe K, Tanaka Y, Kawamori R. Clinical usefulness of measuring urinary polyol excretion by gaschromatography: mass-spectrometry in type 2 diabetes to assess polyol pathway activity. Diabetes Res Clin Pract. 2001;51:115-123.
30. Burg MB, Ferraris JD, Dmitrieva NI. Cellular response to hyperosmotic stresses. Physiol Rev. 2007;87:1441-1474.
31. Krebs JD, Elley CR, Parry-Strong A, et al. The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of highprotein versus high-carbohydrate diets over 2 years in type 2 diabetes. Diabetologia. 2012;55:905-914.